HUTCHMED Completes Phase II Study Enrollment for Fanregratinib
In an exciting development for cancer treatment, HUTCHMED (China) Limited has announced the completion of patient enrollment for its Phase II trial of fanregratinib (HMPL-453). This innovative therapy targets patients suffering from intrahepatic cholangiocarcinoma (IHCC) with specific genetic markers.
Study Overview
This study is designed as a single-arm, multi-center, open-label registration trial assessing the efficacy, safety, and pharmacokinetics of fanregratinib. It focuses on patients with biomarkers indicative of fibroblast growth factor receptor (FGFR)2 fusion/rearrangement, a known contributing factor to tumor progression.
Primary and Secondary Endpoints
The primary endpoint emphasized in this study is the objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), and overall survival (OS). A total of 87 patients have been enrolled to contribute to these vital measures.
Progress and Expectations
Following the first patient’s treatment in early 2023, HUTCHMED anticipates announcing topline results by late 2025. Positive outcomes from this study could catalyze a New Drug Application submission to China’s National Medical Products Administration (NMPA), opening doors for broader patient access to fanregratinib.
About Fanregratinib
Fanregratinib (HMPL-453) is a groundbreaking therapy that acts as a selective inhibitor for FGFR 1, 2, and 3. These receptors play a crucial role in tumor growth and the development of resistance to existing therapies. With abnormal FGFR signaling linked to the proliferation of cancerous cells, fanregratinib aims to disrupt this process effectively.
Understanding IHCC and FGFR2 Fusion/Rearrangement
Intrahepatic cholangiocarcinoma presents a significant challenge in oncology. Identified as a subtype of primary bile duct cancer, it had an estimated 61,900 new cases diagnosed within recent assessment years. Moreover, the growth rate of IHCC cases highlights the pressing need for effective treatment options.
Prevalence and Challenges
FGFR2 fusion or rearrangement has a prevalence rate of approximately 10-15% in IHCC patients, marking a critical area for targeted therapies like fanregratinib. Addressing this unique molecular characteristic is essential for developing personalized treatment strategies.
About HUTCHMED
HUTCHMED stands at the forefront of biopharmaceutical innovation as a commercial-stage company dedicated to discovering and developing targeted therapies and immunotherapies. Their commitment lies in enhancing treatment pathways for cancer and various immunological disorders. To date, HUTCHMED has transitioned multiple drug candidates from discovery into patient care, with their first medicines already making an impact in markets worldwide.
For involvement in impactful cancer research, HUTCHMED retains all global rights to fanregratinib, emphasizing their strategic positioning in this therapeutic sector.
Frequently Asked Questions
What is fanregratinib?
Fanregratinib (HMPL-453) is a selective inhibitor that targets specific fibroblast growth factor receptors associated with tumor growth.
What is the primary focus of the Phase II study?
The Phase II study focuses on evaluating the efficacy and safety of fanregratinib in treating patients with intrahepatic cholangiocarcinoma with FGFR2 fusion/rearrangement.
When are the results from the study expected?
Topline results from the study are anticipated by the end of 2025, contingent on favorable outcomes.
What previous treatments are available for IHCC?
Existing treatments for IHCC include surgical resection, chemotherapy, and radiation therapy, but targeted therapies like fanregratinib represent significant advancements.
How does fanregratinib work?
Research shows that fanregratinib inhibits abnormal FGFR signaling, crucial for tumor growth and resistance to other anti-cancer treatments.
